OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:31 UTC. Every row links to its source record.

TNFSF10 TNF superfamily member 10

ENSG00000121858 · protein coding · Open Targets profile

Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed:10549288, PubMed:26457518). Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis. .

In 6 of 15 cancers, the evidence for TNFSF10 comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751breast carcinomabreast carcinomabreast carcinoma: germline 0.69triple-negative breast carcinomatriple-negative breast carcinomatriple-negative breast carcinoma: germline 0.69luminal A breast carcinomaluminal A breast carcinomaluminal A breast carcinoma: germline 0.64prostate carcinomaprostate carcinomaprostate carcinoma: germline 0.55renal carcinomarenal carcinomarenal carcinoma: germline 0.24renal cell carcinomarenal cell carcinomarenal cell carcinoma: germline 0.19glioblastomaglioblastomahepatocellular carcinomahepatocellular carcinomanon-small cell lung carcinomanon-small cell lung carcinomamelanomamelanomabreast cancerbreast cancercolorectal carcinomacolorectal carcinomaacute myeloid leukemiaacute myeloid leukemiacentral nervous system cancercentral nervous system cancergliomaglioma

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Med-Quality Pocket, Druggable Family
Antibody
UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
PROTAC
Database Ubiquitination, Small Molecule Binder

gnomAD loss of function constraint: o/e 0.4401400089263916 (upper bound 0.6997799873352051). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of TNFSF10's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of TNFSF10's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.